We are live on ! Find out more
PYXS icon

Pyxis Oncology

78 hedge funds and large institutions have $40.5M invested in Pyxis Oncology in 2026 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 11 increasing their positions, 36 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,800% more call options, than puts

Call options by funds: $290K | Put options by funds: $10K

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

17% more capital invested

Capital invested by funds: $34.7M → $40.5M (+$5.8M)

0% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 14

1% less funds holding

Funds holding: 7978 (-1)

4.62% less ownership

Funds ownership: 48.5%43.88% (-4.6%)

69% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 36

Holders
78
Holders Change
-1
Holders Change %
-1.27%
% of All Funds
0.96%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.02%
New
14
Increased
11
Reduced
36
Closed
14
Calls
$290K
Puts
$10K
Net Calls
+$280K
Net Calls Change
-$218K
Name Holding Trade Value Shares
Change
Change in
Stake
P
1
Pfizer
New York
$9.21M
LCM
2
Laurion Capital Management
New York
$7.3M +$303K +200,854 +4%
GGI
3
GordonMD Global Investments
California
$6.02M
VCM
4
Vanguard Capital Management
Pennsylvania
$2.97M +$3.06M +2,033,510 New
HP
5
HealthInvest Partners
Sweden
$1.62M -$633K -420,209 -68%
PAI
6
Palo Alto Investors
California
$1.48M -$40.6K -26,911 -3%
6CM
7
683 Capital Management
New York
$1.31M +$6.56K +4,353 +0.5%
Renaissance Technologies
8
Renaissance Technologies
New York
$1.3M +$242K +160,300 +22%
BlackRock
9
BlackRock
New York
$1.15M +$7.18K +4,762 +0.6%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$874K +$31.5K +20,910 +4%
LP
11
Longaeva Partners
Illinois
$735K
Jacobs Levy Equity Management
12
Jacobs Levy Equity Management
New Jersey
$673K +$695K +460,997 New
Millennium Management
13
Millennium Management
New York
$581K -$521K -345,482 -46%
Marshall Wace
14
Marshall Wace
United Kingdom
$517K -$53.3K -35,347 -9%
DC
15
Decheng Capital
California
$477K
Jane Street
16
Jane Street
New York
$445K -$726K -481,551 -61%
VFT
17
Vanguard Fiduciary Trust
Pennsylvania
$439K +$454K +300,897 New
UBS Group
18
UBS Group
Switzerland
$371K -$209K -138,642 -35%
State Street
19
State Street
Massachusetts
$363K +$10.9K +7,200 +3%
XT
20
XTX Topco
Cayman Islands
$292K -$134K -88,937 -31%
Acadian Asset Management
21
Acadian Asset Management
Massachusetts
$209K +$217K +144,256 New
Bank of New York Mellon
22
Bank of New York Mellon
New York
$196K -$46.8K -31,048 -19%
NW
23
NewEdge Wealth
Pennsylvania
$169K
Northern Trust
24
Northern Trust
Illinois
$149K
BCM
25
Bridgeway Capital Management
Texas
$119K +$12.9K +8,560 +12%

PYXS Hedge Fund Activity: Q1 2026 in Review

78 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q1 2026, worth a combined $40.5M — up 17% from $34.7M a quarter earlier.

Fund positioning in PYXS was balanced in Q1 2026: 14 funds opened new positions, 14 closed out, 11 added to existing stakes and 36 trimmed.

The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $695K. The largest seller was Bank of America, cutting an estimated $861K.

  • 78 institutional investors held Pyxis Oncology (PYXS) as of Q1 2026, down from 79 in Q4 2025.
  • Funds reported $40.5M of Pyxis Oncology stock for Q1 2026, up 17% quarter-over-quarter.
  • 14 funds opened new Pyxis Oncology positions in Q1 2026 and 14 closed out, a net change of 0 holders.
  • The largest Pyxis Oncology buyer in Q1 2026 was Jacobs Levy Equity Management, an estimated $695K added.
  • The largest Pyxis Oncology seller in Q1 2026 was Bank of America, an estimated $861K sold.

Based on aggregated 13F filings for Q1 2026.